Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
LakeShore Biopharma Co., Ltd (LSBCF)
Beijing, CN
LakeShore Biopharma Co., Ltd (LSBCF) is a biopharmaceutical firm dedicated to the end-to-end process of bringing innovative medical solutions to market. Its primary focus lies in creating vaccines and advanced therapeutic biologics, specifically designed to combat infectious diseases and various forms of cancer. A cornerstone of its strategy is the proprietary PIKA immunomodulating technology platform. This innovative platform underpins the development of several key pipeline assets, including a PIKA rabies vaccine, a PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. LakeShore Biopharma maintains operations across an international footprint, with a presence in China, the United States, Singapore, the United Arab Emirates, and the Philippines. Established in 2002, the company was initially known as YS Biopharma Co., Ltd. It rebranded to LakeShore Biopharma Co., Ltd in May 2024. The company's corporate headquarters are located in Beijing, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +21.08% | +44.52% | -65.38% | -94.74% | -94.67% | -96.14% | -99.66% | -99.95% | -99.95% | -99.95% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+7.2% ★ Q1'24: +27.7% (vs Q1'23)
-
EPS growth Biotechnology: +29.7%+76.8% ★ Q1'24: -39.2% (vs Q1'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-32.0% Q1'24: +0.0% (vs Q1'23)
-
EBIT margin Biotechnology: +0.0%-13.9% Q1'24: -68.7% (vs Q1'23)
-
ROIC Biotechnology: -16.1%-9.6% ★ Q1'24: -39.1% (vs Q1'23)
-
Share dilution Biotechnology: -3.4%+0.0% ★ Q1'24: +17.3% (vs Q1'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-8.54× Q1'24: -1.25× (vs Q1'23)
| Metric |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
Mar 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|
| Revenue |
614.96M
est: 791.42M (-22.3%)
|
1.45B
1.45B – 1.45B
+82.7% YoY
|
1.82B
1.82B – 1.82B
+26.2% YoY
|
2.01B
2.01B – 2.01B
+9.9% YoY
|
| EBITDA |
-48.54M
est: -225.01M (+78.4%)
|
-411.04M
-411.04M – -411.04M
-82.7% YoY
|
-518.68M
-518.68M – -518.68M
-26.2% YoY
|
-570.11M
-570.11M – -570.11M
-9.9% YoY
|
| EBIT |
-85.19M
est: -281.53M (+69.7%)
|
-514.28M
-514.28M – -514.28M
-82.7% YoY
|
-648.96M
-648.96M – -648.96M
-26.2% YoY
|
-713.31M
-713.31M – -713.31M
-9.9% YoY
|
| Net Income |
-99.98M
est: -1.90B (+94.7%)
|
1.08B
1.08B – 1.08B
+156.6% YoY
|
3.97B
3.97B – 3.97B
+268.6% YoY
|
4.89B
4.89B – 4.89B
+23.2% YoY
|
| SGA |
390.73M
est: 509.66M (-23.3%)
|
931.00M
931.00M – 931.00M
+82.7% YoY
|
1.17B
1.17B – 1.17B
+26.2% YoY
|
1.29B
1.29B – 1.29B
+9.9% YoY
|
| EPS |
-0.94
est: -17.81 (+94.7%)
|
10.07
10.07 – 10.07
+156.6% YoY
|
37.13
37.13 – 37.13
+268.6% YoY
|
45.73
45.73 – 45.73
+23.2% YoY
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Apex Prospect Limited | 98.36M | 52.23% | — | 98.36M | — | 98.36M | CO | Cayman Islands | 2024-02-14 | ↗ |
| 2 | Fung Ching Wong | 98.36M | 52.23% | — | 98.36M | — | 98.36M | IN | China | 2024-02-14 | ↗ |
| 3 | Yi ZHANG | 39.60M | 42.60% | — | — | — | 38.97M | IN | British Virgin Islands | 2024-02-15 | ↗ |
| 4 | Brilliance Investments Limited | 38.97M | 41.90% | — | — | — | — | CO | British Virgin Islands | 2024-02-15 | ↗ |
| 5 | Hopeful World Company Limited | 4.57M | 14.90% | — | — | — | — | CO | British Virgin Islands | 2024-02-15 | ↗ |
| 6 | Rui MI | 4.57M | 4.90% | — | — | — | 4.57M | IN | British Virgin Islands | 2024-02-15 | ↗ |
| 7 | Xu ZHANG | 2.47M | 2.70% | — | — | — | 2.44M | IN | British Virgin Islands | 2024-02-15 | ↗ |
| 8 | Nan ZHANG | 2.45M | 2.60% | — | — | — | 2.44M | IN | British Virgin Islands | 2024-02-15 | ↗ |
| 9 | Acton Town International Limited | 2.44M | 2.60% | — | — | — | — | CO | British Virgin Islands | 2024-02-15 | ↗ |
| 10 | Apex Pride Global Limited | 2.44M | 2.60% | — | — | — | — | CO | British Virgin Islands | 2024-02-15 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Honggang Teng | Head of Production & Quality Management | — | — |
| Hui Shao | President, Chief Business Officer & Vice Chairman | — | — |
| Rui Yu | Chief Financial Officer & Director | — | female |
| Wang Xu | Chief Executive Officer & Director | — | male |
| Yuan Liu | Head of Vaccine Research | — | — |
| Zhiyuan Ran | Head of Marketing and Sales | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for LSBCF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
